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Abstract
Background: Counterfeit oral artesunate has been a major public health problem in mainland SE
Asia, impeding malaria control. A countrywide stratified random survey was performed to
determine the availability and quality of oral artesunate in pharmacies and outlets (shops selling
medicines) in the Lao PDR (Laos).
Methods: In 2003, 'mystery' shoppers were asked to buy artesunate tablets from 180 outlets in
12 of the 18 Lao provinces. Outlets were selected using stratified random sampling by investigators
not involved in sampling. Samples were analysed for packaging characteristics, by the Fast Red Dye
test, high-performance liquid chromatography (HPLC), mass spectrometry (MS), X-ray
diffractometry and pollen analysis.
Results: Of 180 outlets sampled, 25 (13.9%) sold oral artesunate. Outlets selling artesunate were
more commonly found in the more malarious southern Laos. Of the 25 outlets, 22 (88%; 95%CI
68–97%) sold counterfeit artesunate, as defined by packaging and chemistry. No artesunate was
detected in the counterfeits by any of the chemical analysis techniques and analysis of the packaging
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demonstrated seven different counterfeit types. There was complete agreement between the Fast
Red dye test, HPLC and MS analysis. A wide variety of wrong active ingredients were found by MS.
Of great concern, 4/27 (14.8%) fakes contained detectable amounts of artemisinin (0.26–115.7 mg/
tablet).
Conclusion:  This random survey confirms results from previous convenience surveys that
counterfeit artesunate is a severe public health problem. The presence of artemisinin in
counterfeits may encourage malaria resistance to artemisinin derivatives. With increasing
accessibility of artemisinin-derivative combination therapy (ACT) in Laos, the removal of
artesunate monotherapy from pharmacies may be an effective intervention.
Background
Artesunate is a key anti-malarial artemisinin derivative,
developed in the People's Republic of China (China),
vital for malaria treatment. It is widely used in South East
(SE) Asia and increasingly in Africa for the treatment of
Plasmodium falciparum malaria [1]. Although it should be
used as a component of artemisinin-derivative based
combination therapy (ACT), it is also widely and inappro-
priately sold as monotherapy [2,3]. There is good evi-
dence that ACT, including either artesunate, artemether or
dihydroartemisinin combined with a partner drug of rela-
tively long biological half-life, is the most efficacious anti-
malarial therapy, providing rapid parasite clearance and
reduced gametocyte carriage and, in low or moderate
transmission areas, reducing malaria incidence [1,4,5].
However, since the discovery of counterfeit artesunate in
the late 1990s in mainland SE Asia [6,7], there has been
concern that much of the artesunate used by patients is
counterfeit, containing no or inadequate active ingredient
[3,7-11]. In most countries the private sector is the major
source of anti-malarial drugs and many patients have
relied on artesunate monotherapy (2).
In the Lao People's Democratic Republic (Laos), 38% and
54% of oral artesunate collected, by convenience sam-
pling, in 2000–2001 and 2002–2003, respectively, were
counterfeit [7,9]. The prevalence in Laos reflects the situa-
tion in mainland SE Asia where 38% (2000–2001) and
53% (2002–2003) of oral artesunate were counterfeit
[7,9]. In Asia, the artesunate tablets of one major pro-
ducer, Guilin Pharmaceutical Co. Ltd. (Guilin, Guangxi
autonomous region, China), has been targeted exclu-
sively. The recent description of counterfeit artemisinin
derivatives in six sub-Saharan African countries is of enor-
mous public health concern [12-14]. Counterfeit artesu-
nate containing sub-therapeutic quantities of artesunate
has recently been described in Asia [3,15]. Such counter-
feits, which may foil simple qualitative screening tests,
will engender the selection and spread of artemisinin
derivative resistant falciparum parasites, creating a disas-
trous situation for malaria control in Asia and, thereafter,
in Africa. Sixteen different packaging types of counterfeit
artesunate have been described with diverse chemical rec-
ipes including ineffective anti-malarials, such as chloro-
quine, antibiotics and potentially toxic pharmaceuticals
[3,16,17]. A forensic analysis of the diversity of counterfeit
artesunate suggested that at least some are produced in
southern China, and that there are at least two factories or
networks responsible. One putative network (the 'west-
erly' routes) seems to trade its 'products' through northern
Burma into northern Laos and the Thailand/Burma bor-
der and another (the 'easterly' routes) through Vietnam
into Cambodia and southern Laos [3]. Laos appears to be
afflicted by 'products' flowing along both trade routes.
Public health research has neglected investigations of the
quality of essential medicines, with few reliable data
despite evidence suggesting that it is a major problem
reducing the effectiveness of health care [18-21]. There are
very few reliable published estimates of the prevalence of
counterfeit, substandard or degraded medicines for any
country [20-22]. Estimates of the prevalence of fake
artesunate have all used 'convenience' sampling [7,9],
which is potentially flawed by bias [23]. Biases may over-
estimate or underestimate the prevalence of poor quality
drugs depending on whether the drug collectors, con-
sciously or subconsciously, prefer to find or not find poor
quality medicines. For quantitative estimates of the prev-
alence of counterfeit and substandard medicines and to
allow comparisons through time, a standardized rand-
omized sampling procedure, of sufficient sample size, is
needed [23]. Differentiation between counterfeit, sub-
standard or degraded products is important as this infor-
mation is vital to allow medicine regulatory authorities
(MRAs) to determine appropriate counter-measures. Only
three published studies have apparently used random
sampling [18,24-26].
Stratified random sampling of artesunate in Laos was
therefore undertaken to estimate the countrywide preva-
lence of counterfeit or substandard medicine and to allow
investigation of the impact of any subsequent interven-Malaria Journal 2009, 8:172 http://www.malariajournal.com/content/8/1/172
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tions. This paper has two aims. First, to describe the meth-
odology used to perform the random survey and second,
to present data on the quality of oral artesunate in Laos.
Methods
Study locations and sampling
A stratified random sampling of medicines was performed
to give an unbiased estimate of the proportion of outlets
selling artesunate in Laos between March and June 2003.
As it was not initially known how many licensed pharma-
cies and shops selling medicines there were in each district
or province we did not perform a power calculation. Two
sets of samples were collected. In the first collection, Laos
was stratified into northern and southern provinces as fal-
ciparum malaria has a higher incidence in the south than
in the north (see below, Figure 1) (the Vientiane Province/
Vientiane City and Xiengkuang/Borikhamxay borders
were the dividing line; in 2003 there were 18 provinces,
now 17) and then by rural and urban districts. Provinces
were selected first, with three of the 10 northern Lao prov-
inces and three of the 8 southern Lao provinces randomly
selected. The 42 districts in these selected provinces were
classified as rural (27) and urban (15) on the basis of a
consensus of the Lao Food and Drug Department (FDD)
and Food and Drug Quality Control Centre (FDQCC)
staff bearing in mind district population density, trans-
port conditions and development. One urban and one
rural district were randomly selected from each selected
province. A statistician (Kasia Stepniewska), not involved
in the field sampling, chose the locations using random
number tables from lists of provinces and districts. The
primary sampling units were the randomly chosen outlets
in randomly chosen districts and provinces. Outlets were
divided into licensed pharmacies and shops selling medi-
cines. Itinerant drug sellers were not included. The study
team met with the district and village authorities to
enquire about licensed pharmacies and shops selling
medicines within the study district and lists of outlets
(Table 1, including district hospitals and clinics) in each
study district were used for their random selection. As the
sale of medicines from shops is illegal it is likely that they
are underestimated but, as artesunate was not licensed in
2003, technically all artesunate sold was done so illegally.
In each district, based on what was practical and without
a power calculation, a sampling maximum of seven
licensed pharmacies and three shops was planned. If there
were less than these numbers of pharmacies/shops in a
district, these were sampled without further arrange-
ments. If there were more than seven licensed pharmacies
or three shops selling medicines, those to be sampled
were selected using a random number table. In order to
direct the field teams to the randomly determined outlets,
they were asked, once they had complete lists of outlets,
to telephone the Microbiology Laboratory, Mahosot Hos-
pital. The caller told the Laboratory the district name and
the total number of pharmacies and shops in the lists.
Using a random number table, seven licensed pharmacies
and three shops selling medicines were selected and the
caller given these two sets of numbers. A 'spare' number
was also given for pharmacies and shops in case a phar-
macy/shop was found closed after three attempts to sam-
ple.
A second collection was made as the first collection
yielded few artesunate samples and we therefore chose to
investigate larger population centers which would have
more medicine outlets but with substantial rural popula-
tions and malaria. Fifteen randomly selected pharmacies
in the central district of all six Lao cities (excluding Vien-
tiane as this had already been sampled in the first collec-
tion) with a population >20,000 were sampled. The same
telephone procedure as described above was used. Since
drug regulation is more effective in cities, shops selling
medicines were not expected to be present and therefore
were not included.
Map of the Lao PDR showing distribution of collection sites  with number of pharmacies selling counterfeit artesunate/ number of pharmacies selling artesunate Figure 1
Map of the Lao PDR showing distribution of collec-
tion sites with number of pharmacies selling counter-
feit artesunate/number of pharmacies selling 
artesunate. Provinces with red borders are those sampled 
in the first collection and stars indicate urban districts and 
solid circles indicate rural districts. Cities sampled in the sec-
ond collection are shown as blue triangles. Provinces in grey 
were not sampled. Geographical names follow [44].Malaria Journal 2009, 8:172 http://www.malariajournal.com/content/8/1/172
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For both collections, the drug sampling team consisted of
two FDD/FDQCC Lao Government staff from Vientiane
per province, working in cooperation with staff at the Pro-
vincial and District levels. The Vientiane staff was respon-
sible for making up-to-date lists of pharmacies/shops
according to the sampling plan and the actual drug sam-
pling. The Provincial and District staff assisted with the
updating of Government lists of pharmacies and creating
lists of shops that sold medicines and in the drug collec-
tion through their local knowledge. Once the outlets to be
Table 1: Frequency of genuine and fake artesunate at 180 pharmacies/shops selling medicines sample at random in Laos.
First Collection – randomly selected licensed pharmacies and shops selling medicines in 12 districts in 6 Lao provinces
Province 
District
No. pharmacies/shops 
selling medicines 
recorded
No. pharmacies/shops 
selling medicines 
sampled
Pharmacies/shops 
from which artesunate 
bought
No (%) selling 
counterfeit 
artesunate
% slides positive for P. 
falciparum malaria/
province in 2003 
(number of slides 
checked)
Northern Provinces
Phongsaly
Phongsaly
8/3 7/3 0/0 - 1.5 (1,660)
Phongsaly
May
2/3 2/3 0/0 -
Udomxay
Xay
24/2 7/2 1/0 1 (100) 12 (4,389)
Udomxay
Namor
5/2 5/2 0/0 -
Xayabury
Paklai
24/3 7/3 1/0a 0 (0) 1.4 (21,486)
Xayabuly Khorb 7/2 7/2 0/0 -
Southern Provinces
Vientiane City
Sisattanak
76/0 7/0 0/- - 0.2 (1,008)
Vientiane City
Maypaknum
15/0 7/0 0/- -
Borikhamxay
Bolikanh
15/2 7/2 0/0 - 1.5 (274)
Borikhamxay
Khamkueth
24/0 7/0 0/- -
Sekong
Thateng
6/0 6/0 2/- 2 (100) 17.5 (7,149)
Sekong
Dakcheung
4/0 4/0 3/- 3 (100)
Total 210+17 = 227 73+17 = 90 7/0 6 (86) 5.9 (35,966)
Second collection – randomly selected pharmacies in all 6 Lao cities (excluding Vientiane) of > 20,000 people
City No. pharmacies 
recorded
No. pharmacies 
sampled
Pharmacies from 
which artesunate 
bought
No (%) selling 
counterfeit 
artesunate
% slides positive for P. 
falciparum malaria/
province in 2003 
(number of slides 
checked)
Northern Provinces
Luangphrabang 51 15 0 - 4.6 (16,455)
Xiengkhuang 47 15 1a 0 (0) 0.4 (6,856)
Southern Provinces
Thakhek 68 15 0/ - 2.5 (37,980)
Savannakhet 56 15 6 6 (100)b 11.8 (60,238)
Saravane 23 15 4c 3 (75) 11.8 (29,017)
Pakse 59 15 7d 7 (100) 6.4 (40,523)
Total 304 90 18 16 (89) 7.8 (191,069)
Overall Total 514+17 = 531 163+17 = 180 25 22 (88) 7.5 (227,035)
Geographical names follow [44]. For the First Collection the district in the first row is the urban district and the second row is the rural district.
a genuine labeled as manufactured by Mekophar; b duplicates of artesunate bought at 5 pharmacies in Savannakhet (see Additional File 1);
c genuine labeled as manufactured by Pharbaco d insufficient packaging available for one sample to judge whether counterfeit or genuine but 
chemistry demonstrated wrong active ingredients and therefore classed as counterfeit.Malaria Journal 2009, 8:172 http://www.malariajournal.com/content/8/1/172
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sampled were identified by a telephone call to Vientiane,
they were visited by the Lao 'mystery shopper', unaccom-
panied by anyone who might be linked to the drug regu-
latory authorities. The shoppers, of either gender, were
dressed casually (representing mid-range of Lao socio-
economic status) and stated in Lao language "I would like
to buy some medicine for my family – we are travelling – here
is a list – may I see which ones you have so that I can choose?".
The list was handwritten in Lao on a scrap of paper. If only
one make of a drug was offered the study customer asked
"Do you have any other makes, please?". At least twenty tab-
lets of oral artesunate were requested. If the outlet was
closed, the mystery shopper visited a total of three times.
If the outlet was closed at the third visit, the additional
'spare' code was used and that outlet visited. If the drug
was given without a packet the pharmacist/shopkeeper
was asked for the packet (except if the tablets were taken
from jars this would not be requested).
The maximum number of makes or brands of artesunate
available in each outlet was expected to be five. For outlets
where more than one make of drug was available the
shopper held a handwritten list containing a table for each
shop giving the potential number of makes available (1–
5), with a corresponding random number signifying
which make to sample, counting the medicines from the
left. If the drugs offered were a mixture of different makes
or lot numbers or were past their expiry date they were still
collected. The samples were stored at 4°C until analysis.
The consensus among the investigators was that ethical
review was not necessary.
Sample analysis
Packaging
The physical appearance and printed text on packets, leaf-
let inserts and blisterpacks were examined and compared
with known genuine artesunate. Packets, leaflets and blis-
terpacks were examined with an ×6 hand lens, ×100 ster-
eomicroscope and with a handheld UV (375 nm) light
source and then electronically scanned. Batch numbers,
dates of expiry and manufacture, the colour, clarity and
text of printing on the blisterpack, packet and leaflet
(when present) were documented. Guilin Pharmaceutical
Co. Ltd. kindly informed us which batch numbers were
genuine. Samples were defined as counterfeit and sub-
standard according to WHO definitions [27] and analysis
of packaging was performed blinded to chemical results
and vice-versa. Counterfeit samples were classified on the
basis of the packaging details, especially the design of the
fake hologram, into the different Types as described in [3].
Chemical and biological analysis
The Fast Red Dye test was performed according to Green
et al [28,29]. Additionally, exposure of calcium carbonate
to acetic acid in this test results in the release of carbon
dioxide bubbles. Since Guilin brand tablets do not con-
tain calcium carbonate (chalk), formation of bubbles
would indicate a fake tablet composed of this chemical.
High-performance liquid chromatography (HPLC) assays
for artesunate were performed in 2003–2005 according to
a previously described procedure [30]. For those samples
found to contain artemisinin, chloroquine, pyrimeth-
amine and sulphadoxine HPLC assays were performed
according to the techniques described previously [30].
Mass spectrometry (MS) assays were performed in 2005
following a method previously reported [15]. The HPLC
method used can detect >0.1 mg of active ingredients per
tablet for the medicines investigated here. In contrast, MS
can detect down to picogram-femtogram amounts of
active ingredients per tablet. Artesunate reference stand-
ard (98–102% purity) used for the HPLC analysis was a
generous donation from Mepha AG (Basel, Switzerland).
As reported previously [3], four samples were analysed by
X-ray diffractometry (XRD; X'Pert Pro X-ray diffractome-
ter, Philips, Almelo, The Netherlands) and isotope ratio
MS to determine the mineral composition and by micros-
copy for pollen and invertebrate remains.
Results
180 outlets were sampled, representing 33.9% (180/531)
of all pharmacies and shops selling medicines recorded in
the study areas and 8.1% of all licensed pharmacies in
Laos in 2003 (163/2,014) (Table 1). The majority of out-
lets sampled during the first collection were licensed phar-
macies (81.5%). Shops selling artesunate were found in 7/
12 (58.3%) districts. All pharmacies were Class 3 (i.e.
'with the licensee being neither pharmacist nor assistant
pharmacist' [31].
Artesunate was found in 25 of all 180 outlets (13.9%).
Considering only the pharmacies, 15.3% (25/163) sold
artesunate. No artesunate was bought from shops selling
medicines. Only one brand of artesunate was found in
each pharmacy. Five pharmacies (20%) offered two blis-
terpacks of artesunate and the remaining 20 offered one.
No 'spare' numbers were used as all selected outlets were
open when visited.
Packaging
All samples were sold in blisterpacks. By inspection of
packaging, without knowledge of the chemical results, 26/
30 (87% (95%CI 68–96%)) artesunate samples were
counterfeit, three were genuine (10%) and the classifica-
tion of one sample (12 Pas P2/1) could not be determined
because key parts of the packaging were cut off before sale
(Table 1, Figure 1).
The three genuine samples were labelled as made by
Mekophar Chemical Pharmaceutical Joint-Stock Co. (Ho
Chi Minh City, Vietnam) and Pharcabo (Hanoi, Vietnam)Malaria Journal 2009, 8:172 http://www.malariajournal.com/content/8/1/172
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[32]. All the 26 counterfeits samples and the blisterpack of
uncertain classification were labelled as made by Guilin
Pharmaceutical Co. Ltd. For the 29 samples with an expiry
date stated on the packaging (this was cut from one sam-
ple) the samples were bought before the expiry date. Of
the 16 counterfeit artesunate types, Types 1 (one), 3
(one), 4 (three), 5 (seven), 7 (one), 8 (12) and 11 (one)
[3] were represented. Of the five pharmacies that provided
two blisterpacks, the packaging of the pairs was identical,
except for one shop which sold both packaging Types 5
and 8. One counterfeit had a misspelling of Tablet as
'Tablte' on the blisterpack and one had an unusually long
stated interval between manufacture and expiry date (nine
years) (Additional file 1). Excluding Type 1, which lacking
distinctive features is probably a mixture of different
types, all the packaging types examined have only been
described or have predominantly been described from the
putative easterly distribution of fake artesunate in Laos,
Cambodia and Vietnam [3].
Chemical and botanical analysis
There was 100% agreement between the Fast Red dye test,
HPLC, and MS for the 30 samples labelled as artesunate.
All those classified as counterfeit, based on the packaging,
contained no detectable artesunate. Chemical analysis of
the sample with insufficient packaging (above) was
shown by MS to contain pyrimethamine, sulphadoxine,
and paracetamol, but no artesunate and was, therefore,
counterfeit (Additional file 1). The combination of pack-
aging and chemistry demonstrates that 27/30 (90%)
(95%CI 72–97%) of artesunate samples were counterfeit.
In terms of outlets, 22/25 (88%) (95% CI 68–97%) sold
fake artesunate. The three genuine samples contained a
median (range) artesunate content/tablet of 49.2 (45.1–
50.3) mg (all had stated tablet content of 50 mg artesu-
nate). The 27 counterfeit samples that underwent forensic
MS were found to contain paracetamol (16), sulphadox-
ine (12), dimethylfumarate (6), metamizole (5),
pyrimethamine (8), erythromycin (5), artemisinin (4), 2-
mercaptobenzothiazole (3), chloramphenicol (2), chlo-
roquine (1) and erucamide (1). The concentrations of
artemisinin as determined by HPLC were 0.26, 4.50, 6.50
and 115.7 mg/tablet, chloroquine 14.7 mg/tablet,
pyrimethamine 17.1, 16.0, 16.6 mg/tablet and sul-
phadoxine 409.6, 385.9, 413.9 mg/tablet (Additional file
1). Of 12 and 8 samples found by MS to contain sul-
phadoxine and pyrimethamine, respectively, sulphadox-
ine and pyrimethamine were found by HPLC in only three
and three samples, respectively. The ratios of pyrimeth-
amine to sulphadoxine, normally 1:20 in sulphadoxine-
pyrimethamine (SP) coformulated tablets, were 1:24.0,
1:24.1 and 1:24.9 – suggesting that the counterfeits may
have been formulated from powder after the co-drugs had
been mixed to manufacture SP tablets. Of 4 samples
examined with XRD, calcite was detected in three and
starch in one. The stable isotope analysis of the calcite sug-
gested a high temperature or volcanic origin as previously
reported [3]. The results from the pollen analysis are con-
sistent with a source of the fake artesunate in southern
China, but do not prove this geographical origin as dis-
cussed in [3].
Geographical distribution
Artesunate was bought in seven of the 12 (58.3%) Lao
provinces sampled, more frequently in southern Laos. The
median (range) percentage of pharmacies selling artesu-
nate in the sampled provinces were 0 (0–6.3) % and 27
(0–50) % in the northern and southern provinces, respec-
tively (Figure 1). The seven sampled provinces with a slide
positivity rate (all Plasmodium species) (SPR) <5% had a
median (range) percentage of outlets selling artesunate of
0 (0–7)% and the five sampled provinces with an SPR of
≥5% had a median (range) percentage of outlets selling
artesunate of 40 (6–50)%. With the exception of
Udomxay, the more malarious sampled provinces were all
in southern Laos – the median (range) SPR was 1.5 (0.4–
12) % in the northern sampled provinces and 6.4 (0.2–
17.5) % in the southern sampled provinces. Provinces
with more malaria (higher SPR) in 2003 were also those
with a higher proportion of pharmacies selling artesunate
(Table 1, Figure 2). In the first collection, the median
(range) number of outlets per urban district was 22 (6–
76) and 8 (4–17) per rural district. 3/6 urban and 1/6
rural districts contained outlets that sold artesunate and 3/
4 and 3/3 of outlets in urban and rural districts, respec-
tively, sold counterfeit artesunate.
Discussion
Malaria remains an important clinical problem in Laos,
with 14,997 patients with P. falciparum recorded in 2008
Plot of slide positivity rate (SPR%) against the percentage of  outlets selling artesunate for 12 Lao provinces Figure 2
Plot of slide positivity rate (SPR%) against the per-
centage of outlets selling artesunate for 12 Lao prov-
inces. R2 = 0.60, P = 0.01. Circles indicate the first collection 
and triangles the second collection.Malaria Journal 2009, 8:172 http://www.malariajournal.com/content/8/1/172
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and five Lao provinces (all in the south) having >1,000
cases/year (unpublished data Centre for Malariology, Par-
asitology and Entomology, Vientiane (CMPE)). The ran-
dom sampling survey reported here estimates that 13.9%
of outlets in Laos sold oral artesunate but that it was more
available in the malarious southern provinces. In an anti-
malarial drug use survey in seven districts in the malarious
provinces of Luangnamtha, Savannakhet and Attapeu
Provinces in 2004 (unpublished data CMPE 2004), 5.5%
of private sector and 11.1% of public sector outlets had
artesunate tablets in stock. Both these surveys were con-
ducted before the introduction of ACT by the Lao Govern-
ment in 2005.
However, 88% of 25 pharmacies sampled in Laos in 2003
sold counterfeit artesunate. Substandard artesunate has
been described from Thailand and Cambodia [3,33] but
in Laos all the poor quality artesunate were counterfeit.
This compares with previous estimates of the frequency of
counterfeit artesunate of 38% in 2000–2001 [7] and 54%
in 2002–2003 [9], but these studies used convenience and
not random sampling. The results from convenience and
random sampling are not comparable as different sam-
pling frames and sampling methods were used. The ran-
dom sampling methodology, which included 8% of
licensed pharmacies in Laos, reduced the risk of bias –
assuming the collectors followed the randomisation
instructions – by eliminating the collectors' ability to
decide which outlets to sample. That no artesunate was
bought from shops selling medicines may not reflect the
reality for patients and their relatives as the shop owners
may have been more reluctant to take the risk of selling
this product to an outsider.
Lot quality assurance sampling (LQAS) was recently pro-
posed as the first step in assessing drug quality [23], but,
as convenience sampling already suggested that there was
a severe problem of counterfeit artesunate in Laos, a con-
ventional randomized survey was performed. The major-
ity of the details listed in the Medicine Quality Assessment
Reporting Guidelines (MEDQUARG) [23] are reported.
Limitations of this study include that we did not sample
itinerant sellers who may also stock oral artesunate, the
number of shops selling medicines sampled was relatively
small and may have been underestimated, that we did not
perform dissolution tests and urban and rural districts
were not formally defined. Apart from a larger number of
outlets in urban than rural districts there were no clear dif-
ferences between the two district types. Although, a for-
mal definition of urban districts was not used, there is no
agreed definition of 'urban' [34] and all the urban districts
sampled included rural farming areas. Of note the median
(range) population of the six cities in the second collec-
tion was only 65,592 (20,239–200,462). Figure 2
includes both 'cities' and the urban and rural districts –
they both demonstrate the same trend with increased
availability of artesunate at higher provincial SPR. Lao cit-
ies and urban districts have small population size and are
close to rural and malarious Laos, making the differences
that one would expect in countries with larger disparities
between urban and rural less pronounced in terms of
medicine availability. Final chemical analysis was per-
formed after the expiry date as stated on the packaging,
although samples were stored at 4°C until analysis. MS
did not give any strong evidence of artesunate degradation
products, which would have been expected if this delay
was significant.
Unsurprisingly, both genuine and counterfeit artesunate
were both more commonly bought in the more malarious
parts of Laos. Concentration of the survey in the more
malarious southern areas would have increased power to
find fake artesunate but in 2003 'clinical' malaria (ie with-
out slide confirmation) was a diagnosis widespread in
Laos. The different results obtained by MS and HPLC for
the frequency of fakes containing sulphadoxine and
pyrimethamine wrong active ingredients presumably
reflect the lower limit of detection for these compounds
by MS in comparison to HPLC. The findings are consistent
with an origin of the Lao samples in the putative easterly
fake artesunate trade network as suggested by the larger
sample in [3]. If this is correct the recent disruption of the
putative westerly trade network in SW China and northern
Burma (Myanmar) [3] is unlikely to have reduced the fre-
quency of fake artesunate in southern Laos.
Fake and substandard drugs are important but poorly rec-
ognized causes of death and disability to individual
patients. They are also important to the whole of society
as the exposure of pathogens, such as malaria parasites, to
sub-therapeutic doses of antimicrobials will encourage
the selection and spread of parasites resistant to the drugs
[35]. The most resistant P. falciparum occur in SE Asia and
multi-drug resistance to malaria remains a serious clinical
problem. There is evidence that malaria parasites bearing
high-level pyrimethamine resistance originally arrived in
Africa from SE Asia [36].
Falciparum malaria resistant to artemisinin derivatives
has started to appear on the Thailand/Cambodia border
and urgent investigations and containment are being per-
formed [37,38] (White NJ pers. comm.). Of considerable
public health concern is that 14.8% of the fake artesunate
collected contained artemisinin, from which artesunate is
derived. The conventional dose of artemisinin in genuine
tablets is 250 mg, whereas the artesunate fakes contained
0.26 – 115.7 mg artemisinin/tablet, suggesting that these
fakes would be subtherapeutic and would engender
artemisinin resistance. Counterfeit or substandard artesu-
nate containing subtherapeutic quantities of artesunateMalaria Journal 2009, 8:172 http://www.malariajournal.com/content/8/1/172
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have been found on the Thailand/Burma border [3,15], in
Cambodia [3] and Thailand [33]. The mechanisms of
resistance to artemisinin and the artemisinin-derivatives
remain unclear but evidence for other anti-infective drugs
suggests strongly that inadequate dosing is a major factor
in selecting resistance. If poor quality medicines contain-
ing sub-therapeutic amounts of artesunate and/or artem-
isinin are widespread it should be assumed that they will
increase the risk of the catastrophic spread of artesunate
resistant malaria in Asia and thence to Africa.
It has been suggested that with the widespread use of ACT
and withdrawal of ineffective medicines, such as chloro-
quine, malaria sensitivity to these drugs may return – as
has been demonstrated in Malawi [39]. However, this will
be dependent on the actual withdrawal of the abandoned
medicines and with 44%, 30% and 4% of fake artesunate
containing sulphadoxine, pyrimethamine and chloro-
quine, respectively, parasites are still being covertly
exposed to these medicines. Conventional genuine chlo-
roquine tablets contain 250 mg salt/tablet and SP con-
tains pyrimethamine 25 mg and sulphadoxine 500 mg/
tablet. As fake artesunate containing 14.7 mg chloro-
quine/tablet, and a median of 16.6 mg pyrimethamine
and 403.1 mg/tablets sulphadoxine were found, it would
be expected, depending on their pharmacokinetic/phar-
macodynamic interactions, that these would select for the
preferential survival of parasites with resistance mutations
[35]. The wide range of non-standard concentrations of
wrong active ingredients in tablets also suggests that these
fake artesunate tablets are not recycled chloroquine,
artemisinin and SP tablets but made of mixtures of pow-
ders by factories formulating anti-malarial drugs. That the
ratios of pyrimethamine to sulphadoxine in the fake
artesunate were close to the conventional ratio of SP tab-
lets of 1:20 suggests that powder used in these fakes was
being diverted from the manufacturer of SP. This raises
the possibility that some of the fakes are being manufac-
tured in a factory producing SP.
It was recently argued [40] that the relatively low preva-
lence of P. falciparum parasites in Laos with markers of
antifolate resistance is a consequence of infrequent use of
this class of anti-malarial in the country. This may change
if current fake anti-malarials contain sulphadoxine and/or
pyrimethamine. The presence of sulphadoxine in many of
the counterfeits poses serious hazards for patients with
allergies to sulpha drugs. Furthermore, 19% of fake artesu-
nate contained metamizole, contraindicated in patients
with glucose-6-phosphatase deficiency, which is common
in Laos, and may precipitate haemolysis.
Monotherapy with artemisinin-derivatives is not recom-
mended in most clinical situations [2,41] and ACT (arte-
mether-lumefantrine) has been rolled out in Laos since
2005. However, recent evidence from adjacent Cambodia
suggests that the majority of malaria patients still receive
artesunate monotherapy despite subsidy of ACT in both
the public and private sectors [2]. Comparable published
data from Laos are not available. Investigations on the
comparative availability of artesunate and ACT, and their
quality, through the informal sector, such as grocery
shops, and pharmacies in SE Asia may help guide appro-
priate interventions. There is an urgent need to determine
the spectrum of unexpected active ingredients, especially
artemisinin, among fake artesunate sold on the Thailand/
Cambodia border area, which is ~400 km from southern
Laos, out of concern that these may help drive resistance
to the artemisinin derivatives [42]. An effective strategy to
improve the anti-malarial therapy that patients receive
and reduce the exposure of parasites to sub-therapeutic
amounts of artemisinin/artesunate in fake artesunate,
may be the removal of artesunate monotherapy (both
genuine and fake) from pharmacies as ACT becomes
available to all potentially malarious patients through the
public and private sectors [43].
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